This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Patterson AL , Greenberg RE , Weems L , Bahnson R , Wajsman Z , Israel M , Sweatman T , Webber D , Gulfo J
Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer
Urology. 2000 Aug;56(2) :232-235
AbstractObjectives. To assess in a pilot study the safety, tolerability, and technical feasibility of administering intravesical valrubicin immediately after transurethral resection of bladder tumors (TURBT) in patients with superficial bladder cancer and to evaluate the optimal dose of valrubicin and its systemic absorption. Methods. Twenty-two patients with recurrent or newly diagnosed Stage Ta or T1 transitional cell tumors received a single dose of 400 mg, 600 mg, or 800 mg of intravesical valrubicin immediately after TURBT, Four patients thought to be at high risk of recurrence were followed up with five additional doses of 800 mg valrubicin, given weekly. Results. The use of valrubicin after TURBT was generally well tolerated, Little evidence was found to suggest a direct relationship among the dose of valrubicin, the time between the end of TURBT and drug instillation, and the occurrence of most bladder symptoms. The most commonly reported adverse events included dysuria (77%), hematuria (59%), and urgency/frequency (23%), Pharmacokinetic analyses revealed that the mean systemic exposure to valrubicin and its metabolites depended on the extent of the TURBT and the damage to the bladder wall. Conclusions. The results of this study indicated that administration of valrubicin immediately after TURBT is feasible. UROLOGY 56: 232-235, 2000. (C) 2000, Elsevier Science Inc.
NotesTimes Cited: 0 English Article 341CT UROLOGY